Inhale slips on potential Exubera delay

INHL was off $1.64 to $18.27 on Tuesday after partner Pfizer (PFE) said in its earnings statement that the planned NDA and MAA filings for the companies' Exubera inhaled insulin are likely to be delayed by the need for more data. PFE said the filings are slated for later this year, but added that "if additional data are required, as now appears likely, the filing schedule will be revised." ...